Glycaemic control in type 2 diabetes: Targets and new therapies

Keyphrases

• Type 2 Diabetes Mellitus (T2DM) 100%
• New Therapies 100%
• Glycemic Control 100%
• Targeted Therapy 100%
• Incretin-based Therapy 60%
• Dipeptidyl peptidase-4 (DPP-4) 40%
• Antidiabetes Agent 40%
• Health Systems 20%
• Disease Progression 20%
• Cardiovascular Risk 20%
• Weight Loss 20%
• Cardiovascular Disease 20%
• Combination Therapy 20%
• Monotherapy 20%
• Current Therapies 20%
• Low Risk 20%
• Pharmacotherapy 20%
• Hypoglycemia 20%
• Weight Gain 20%
• Future Therapies 20%
• Hypoglycemia Risk 20%
• New Therapeutic Approaches 20%
• Sulfonylurea 20%
• β-Cell Survival 20%
• Morbidity Mortality 20%
• Public Health Risk 20%
• Inhibitor-1 20%
• Economic Consequences 20%
• Glucose-stimulated Insulin Secretion 20%
• Weight Neutral 20%
• Control Disease 20%
• GLP-1 Analogue 20%
• Incretin Mimetics 20%
• Glucagon Suppression 20%

Medicine and Dentistry

• Maturity Onset Diabetes of the Young 100%
• Glycemic Control 100%
• Incretin 80%
• Hypoglycemia 40%
• Dipeptidyl Peptidase-4 Inhibitor 40%
• Drug Therapy 20%
• Health Care 20%
• Public Health 20%
• Cardiovascular Disease 20%
• Cell Survival 20%
• Combination Therapy 20%
• Beta Cell 20%
• Monotherapy 20%
• Disease Exacerbation 20%
• Side Effect 20%
• Cardiovascular Risk 20%
• Contraindication 20%
• Sulfonylurea 20%
• Omeprazole 20%
• Glucagon 20%
• Insulin Release 20%
• Glucagon Like Peptide 1 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Non Insulin Dependent Diabetes Mellitus 100%
• Incretin 80%
• Hypoglycemia 40%
• Dipeptidyl Peptidase IV Inhibitor 40%
• Combination Therapy 20%
• Monotherapy 20%
• Disease Exacerbation 20%
• Cardiovascular Disease 20%
• Side Effect 20%
• Cardiovascular Risk 20%
• Pharmacotherapy 20%
• Omeprazole 20%
• Sulfonylurea 20%
• Glucagon-Like Peptide-1 20%
• Glucagon 20%